Choose Broker

Step 1
Choose a broker


Please enter your User ID and Password to place trade

Share or CFD

Step 2
Select the investment product you wish to purchase

OR

Share

Purchasing shares in a company buys you part ownership of that company. You're given the right to vote on who manages the company and receive a portion of company profits through the distribution of dividends.

Example: If a share price quote is $25, then that means one share is valued at $25.

Note: Shares are also referred to as stocks, equities and securities.

CFD

Is an abbreviation for "Contract for Difference". A CFD is a 'derivative' that is derived from the underlying value of the share price. A CFD’s allow you to go long (buy the CFD) or go short (sell the CFD).

CFD's give you leverage.

Example: Buying a CFD in XYZ provides you with an opportunity to purchase the shares at a variable rates such as 10 to 1 ratio instead of the full upfront share value cost i.e. paying $1,000 instead of $10,000.

Because CFDs are traded on margin, you must maintain the minimum margin level at all times.

Note: CFD’s are not recommended for novice traders.

Order Type

Step 3
Select your type of market order


Market Order

This is a type of order that instructs to buy or sell immediately at the best price available.

Limit Order

An order placed to buy or sell a set number of shares at a specified price or better.

Stop Order

This is an order that is executable once a set price has been reached. Once the order surpasses a particular point the order becomes a market order.

Stop Limit Order

An order placed that will be executed at a specific price or better after a given stop price has been reached. Therefore it combines the feature of a stop order with those of a limit order.

Order Period

Step 4
Select the time period that you want your trade to be live/active for.


G.T.C

Stands for good till cancelled. This means once the order is placed, the order will remain in place until someone cancels the order.

Day order

An order that if not executed, will stand until the end of the trading day.

One week

An order that will stand for a full week from the time it is placed, and then be automatically cancelled at the end of this period if it has not been executed.

One month

An order that if not executed, will stand for a full month.

End of week

An order that if not executed, will stand to the end of the trading week.

End of month

An order that if not executed, will stand to the end of the trading month.

End of year

An order that if not executed, will stand to the end of the year.

Quantity

Step 5
Select the value or quantity of how many shares you want to buy

Shares
@
$

Brokerage Fee: Please select broker first to calculate brokerage*.

Nominal Value:
$71.50 AUD

Risk Management

Step 6
Select what alarms (automatic exits) you want to protect both your investments and your profits.

Take Profit
$
OR
%
Stop Loss
$
OR
%
Trailing Stop Loss
%

Take Profit

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Trailing Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Confirm

Confirm
Please confirm your order

Buy -
Order Type -
Price -
Order Period -
Brokerage 8.00 AUD
Nominal Value -
Take Profit -
Stop Loss -
Trailing Stop Loss -
Trade Date -
There was a problem with your trade ticket. Please try again.
There was a problem submitting your trade ticket. Please try again in a minute.

Order Placed Successfully


Exit Orderpad        Place another trade
Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{quote['Price Qualifier Code'] == "OPN" ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Novogen Limited (NRT)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

News

No News Available

{{item.Body}}



General Overview

Novogen's Story

        Novogen has focused on breaking through this roadblock. Their objective has been to find ways both to kill the cancer stem cells, as well as augmenting the cytotoxic effect of standard drugs in their ability to kill the regular cancer cells.

        The most powerful and most effective anti-cancer agents ever developed are known as cytotoxic drugs, meaning that they kill cancer cells by inflicting lethal damage. Cytotoxic chemotherapy has been the mainstay of cancer therapy for the past 40 years and is set to continue to hold that position for the foreseeable future. But cytotoxic chemotherapy has hit a roadblock. It has not advanced in any meaningful way in the last 20 years for two fundamental reasons:

        • First, it has no effect on cancer stem cells, those minority cells within a tumor that are responsible for perpetuating the tumor. So that even where initial response to therapy has occurred, malignant cancer almost always returns;
        • Second, most forms of cancer either have from the start or quickly develop drug-resistance mechanisms that render them insensitive to cytotoxic drugs.

        In this quest, Novogen scientists have identified two new drug targets.

        One target is a family of secondary or enabling mutations that they believe are common to all cancer cells and which are essential for a cancer cell's survival. They have developed a family of drugs that hit this target and for the first time kill the full range of cells within a tumor, but most importantly the cancer stem cells. This is the super-benzopyran drug technology (SBP).

        The second target is a structural protein that when disabled, causes the cancer cell's cytoskeleton to disintegrate. They have developed a drug that by hitting this target greatly potentiates the anti-cancer effect of some of the most widely used drugs in oncology. This is the anti-tropomyosin drug (ATM).

        History

        Novogen was formed in 1994 when it listed on the Australian Securities Exchange (ASX). It obtained a dual listing on NASDAQ in 1998 where it trades ADSs under (NVGN).

        From 1994-2012, the Company focused on the development of drugs based on a simple benzopyran chemical structure. Four anti-cancer drugs were developed with three of these (phenoxodiol, NV-143 and NV-344) being taken into the clinic.

        Subsidiary company, Marshall Edwards Inc (now renamed MEI Pharma Inc) was listed on NASDAQ in 2002. All benzopyran intellectual property was devolved from Novogen to MEI Pharma in 2012.

        In December 2012, private biotechnology company, Triaxial Pharmaceuticals Pty Ltd, conducted a reverse takeover of Novogen, severing all connection with MEI Pharma through an in specie share distribution of its 60% ownership of MEI Pharma.

        Triaxial Pharmaceuticals had developed a new generation of benzopyran drug candidates known as super-benzopyrans (SBPs).

        In mid-2013, Novogen acquired the anti-tropomyosin drug technology from Australian biotechnology company, Genscreen Pty Ltd, to complement its SBP drug platform.

        Vision

        To become a major global biotechnology company on the back of two drug technologies that they believe are set to revolutionise the treatment of degenerative diseases including cancer.

        To convert life-threatening and debilitating diseases of the community into chronic, manageable diseases.

        Specifically in the case of cancer to develop therapies:

        • That will provide meaningful survival benefits for most forms of adult and paediatric cancer; and
        • That will become standard of care first-line therapies for most forms of cancer based on their abilities to eradicate the full hierarchy of cells within a cancer.

        Therapeutic Field

        Oncology
        Cantrixil (TRXE-002-1)

        Cantrixil is a cyclodextrin-based formulation of the active ingredient, TRXE-002-1, which has shown in vitro and in vivo anti-cancer activity in a range of tumour types.

        Novogen anticipates that, if approved, the drug product would be used as an intra-peritoneal chemotherapy, either alone or in combination with other agents, and in one or more cancers of the abdominal cavity (eg ovarian, uterine, colorectal and gastric carcinomas).

        A first-in-human clinical study is planned  to commence in the second half of 2016.

        The particular feature of TRXE-002 is its ability to kill the full hierarchy of cells within a tumor including the cancer stem cells, the regular somatic cancer cells, and the various structural components of a tumor.


        Trilexium (TRXE-009)

        Trilexium (TRXE-009) is Novogen's second SBP drug candidate.

        It has shown evidence of potent anti-cancer activity across a wide range of tumour types, and additional preclinical work is underway to further characterise the drug’s activity, and to identify potential indication(s) for clinical development.


        Anisina (ATM-3507)

        Anisina (ATM-3507) is the first drug candidate in Novogen's anti-tropomyosin (ATM) program.

        Based on initial research at the University of New South Wales (UNSW), the ATM family have been developed through a rational drug design program to target the Tpm3.1 protein, a critical structural component of cancer cells.

        Anisina has been shown to be effective in vitro and in vivo against a broad range of cancer types, including neuroblastoma and prostate cancer.

        The drug is currently undergoing IND-enabling toxicology studies in preparation for the initiation of clinical trials.


        Degenerative Diseases, Autoimmune Diseases & Regenerative Medicine
        Jacob's Hope

        Jacob's Hope is the name they have given to the degenerative and regenerative diseases program that is highly experimental and investigational.

        It is names after a very brave young man called Jacob who has a disease known as Duchenne muscular dystrophy (DMD). Jacob and thousands of children like him around the world, is the reason they are running this program.


        Price History

        52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
        ${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
        Date Open High Low Close Volume

        Dividend Information

        Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
        {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}

        Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
        {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate}} {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.DividendPayDate == '00/01/1900' ? '-' : item.DividendPayDate}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '00/01/1900' ? '-' : item.DividendReinvestmentDeadline}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

        Share Statistics

          Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
        Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
        Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
          Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
        Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
        Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
        5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
        Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
        {{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
        Common Shareholders Shares Outstanding Shares Issued Float
        {{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
        Index Code Index name
        {{item}} {{generalInfo.IndexMembership[item]}}
        N/A N/A
        Order Industry Type Code Mnemonic Reported
        N/AN/AN/AN/AN/AN/A
        {{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

        Valuation Ratios

          P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
        Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
        TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
          Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
        Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
        Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
        Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
        Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
        Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
        Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
        Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

        Financial Strength Ratios

          Current ratio Quick ratio LT debt/equity Total debt/total equity
        Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
        Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
          Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
        Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
        Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
        Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
        Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
          Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
        1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
        Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
        5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
        Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
        Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
        Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
        Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

        Management Effectiveness Ratios

        Turnover Asset Inventory Receivables
        Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
        Return on Average Assets EBITD Equity Investment
        Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
        5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
        Employees Net Income Revenue
        Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
        Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

        Growth Ratios

        Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
        Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
        5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
        3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
        TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
        CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
        5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
        5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

        Forecast Ratios

        Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
        {{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
        ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
        {{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
        ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
        {{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
        ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
        {{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
        TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
        {{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
        EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
        {{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
        ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
        {{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
        ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
        {{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

        Financial Reports

        Financial Summary

        Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

        {{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


        Accounting Notes
        Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

        {{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

        -

        - - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
        Fiscal Period
        Period End Date:
        Period Length
        Ratios Value
        Analyst Footnotes

        Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

        {{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



        Directors, Officers & Company Executives

        Start Date End Date
        {{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
        {{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
        No Directors, Officers & Company Executives Information Found.

        Recommendation Statistics

        No Recommendation Statistics

        Recommendation Statistics
        Recommendation Number Of Analysts
        {{stats.Recommendation}} {{stats.NumberOfAnalysts}}
        I/B/E/S Mean
        {{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
        • Sell
        • Reduce
        • Hold
        • Buy
        • Strong Buy

        Past Broker Recommendations

        No Past Recommendations

        Past Broker Recommendations
          Strong Buy Buy Hold Underperform Sell Total
        {{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

        Target Price

        No Target Price

        Target Price
        Mean {{priceTarget.Mean}}
        High {{priceTarget.High}}
        Low {{priceTarget.Low}}
        Median {{priceTarget.Median}}
        Standard Devitation {{priceTarget.StandardDeviation}}
        Number Of Estimates {{priceTarget.NumberOfEstimates}}

        Videos

        No Videos Found

        Click here to view video

        {{video.summary}}




        Contact Info

        Novogen Limited

        Suite 1.02
        16-20 Edgeworth David Avenue
        Hornsby, NSW
        Australia, 2077

        Phone: +61 2 9472 4100
        Fax: +61 2 9476 0388
        Email: info@novogen.com
        Website: http://www.novogen.com/

        Click here to view the interactive map
        Novogen Limited Google Map
        Novogen Limited Google Map

        Share Registry

        Computershare Investor Services Pty Limited - Click here to view share registry profile

        Phone: +61 3 9415 5000
        Fax: +61 3 9473 2500
        Email: investor.relations@computershare.com.au
        Website: http://www.computershare.com/

        452 Johnston Street
        Abbotsford, VIC
        AU Australia, 3067


        Important Information

        This profile was last edited on 05 Jul 2016.

        All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

        Please read our Terms & Conditions and Disclaimer Statement for further information.

        Home

        Search

        Login

        Register

        Report a bug